Article Sidebar
Published:
Aug 4, 2017Keywords:
Article Details
The author(s) retain copyright on work published by AOSIS unless specified otherwise.
Licensing and publication rights
Author(s) of work published by AOSIS are required to grant AOSIS the unlimited rights to publish the definitive work in any format, language and medium, for any lawful purpose. AOSIS requires journal authors to publish their work in open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
The authors retain the non-exclusive right to do anything they wish with the published article(s), provided attribution is given to the applicable journal with details of the original publication, as set out in the official citation of the article published in the journal. The retained right specifically includes the right to post the article on the authors’ or their institution’s websites or in institutional repositories.
Previously published work may have been published under a different licence. We advise the community that if they would like to reuse the work to consult the applicable licence at article level.
Note: If you need to comply with your funding body policy, you can apply for the CC BY license after your manuscript is accepted for publication.
Main Article Content
Review Article: Ocular allergy
Abstract
Aim: To systematically review relevant literature investigating the classification and nomenclature, epidemiology and pathophysiological mechanisms, as well as diagnosis and treatment of ocular allergy.
Method: The Medline, PubMed, Elsevier Science Direct, and Google Scholar databases were used to search for evidence-based literature on ocular allergy.
Main outcome measures: Classification and nomenclature, epidemiology and pathophysiological mechanisms, diagnosis and management of ocular allergy.
Results: The search retrieved 5200 number of studies of which 6 met the criteria.
Conclusions: While numerous studies regarding pharmacological and immunological research have identified new treatment options, there is a dearth of clinical studies to discover the biomarkers and immune therapeutic management to control sensitisation and effector phases of this condition. Given the complexity of this condition due to the multifactorial nature of the possible aetiologies, rigorous well-designed scientific studies are needed to determine the exact classification, prevalence and underlying immune pathological processes of ocular allergy.
Keywords: Ocular allergy, Perennial conjunctivitis, Allergic conjunctivitis, Atopic kerato conjunctivitis, Vernal keratoconjunctivitis, Giant papillary conjunctivitis
